Haemonetics (HAE)
Haemonetics Revenues: 186.67M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
HAE Revenues Rankings
| Overall | 58th percentile | 1819 of 4425 |
| Sector | 74th percentile | 120 of 470 in Healthcare |
| Industry | 74th percentile | 17 of 67 in Medical Instruments & Supplies |
HAE Revenues Range, Past 5 Years
| Minimum | 121.18M | Sep 2007 |
| Maximum | 191.16M | Dec 2011 |
| Average | 158.21M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these HAE related companies
HAE News
Haemonetics to Present at the Jefferies 2012 Global Healthcare Conference
May 22, 8:00AM PR Newswire
May 22, 8:00AM PR Newswire
Listen to $HAE Haemonetics Investor Roundtable - live at 10:00 AM, ondemand after - http://stks.co/3lV7
about 20 days ago by earningscast
about 20 days ago by earningscast
$HAE Insider Sale: $1.4M of stock sold by Mark Kroll on May 4, 2012 http://stks.co/3jXC
about 21 days ago by MarketBrief
about 21 days ago by MarketBrief
Haemonetics Releases Next Generation of IMPACT® Online Blood Utilization Portal
May 08, 8:00AM PR Newswire
May 08, 8:00AM PR Newswire
Haemonetics to Present at Bank of America Merrill Lynch 2012 Health Care Conference
May 03, 4:30PM PR Newswire
May 03, 4:30PM PR Newswire
$HAE Insider Sale: $1.6M of stock sold by Joseph Forish on May 1, 2012 http://stks.co/3eqG
about 26 days ago by MarketBrief
about 26 days ago by MarketBrief
$HAE Insider Sale: $2.5M of stock sold by Mikael Gordon on May 2, 2012 http://stks.co/3eq9
about 26 days ago by MarketBrief
about 26 days ago by MarketBrief
4 Stocks Hit 52-Week Highs http://stks.co/3aGr My story via @TheStreet $KFT $CMCSA $MMC $HAE #52WeekHigh
about 29 days ago by azendrian
about 29 days ago by azendrian
Listen to $HAE Q4 2012 earnings call - live at 08:00 AM, ondemand after - http://stks.co/3ZlB
about 30 days ago by earningscast
about 30 days ago by earningscast
$PLL Announces 10:00 a.m. EDT Webcast on Monday, April 30 to Discuss Agreement to Sell Blood Product Lines. $HAE http://stks.co/3ZdN
about 30 days ago by abubnic
about 30 days ago by abubnic
$HAE Signs Definitive Agreement To Acquire Hemerus Medical, LLC http://stks.co/3ZNq
about 31 days ago by abubnic
about 31 days ago by abubnic
Raymond James Starts MedTech Sector: CFN, COO, COV at Strong Buy, SLTM, ISRG, BAX at Outperform, BDX at Underperform
Apr 25, 10:00AM Street Insider
Apr 25, 10:00AM Street Insider
Haemonetics Sets Date for Fourth Quarter and Year End Fiscal Year 2012 Earnings Release: April 30, 2012
Apr 05, 4:00PM PR Newswire
Apr 05, 4:00PM PR Newswire
$HAE forms bearish "Double Top" chart pattern. http://stks.co/2epj
about 88 days ago by RecogniaEvents
about 88 days ago by RecogniaEvents
Haemonetics to Present at Leerink Swann 2012 Global Healthcare Conference
Feb 06, 8:00AM PR Newswire
Feb 06, 8:00AM PR Newswire
Listen to $HAE Q3 2012 earnings call (EPS 0.72 vs est 0.8) - live at 10:00 AM, ondemand after - http://stks.co/29It
about 121 days ago by earningscast
about 121 days ago by earningscast
$HAE http://chart.ly/7gchxmn Haemonetics -$1.7B Blood Bank Co. - Finally Breaking Range with 11 Days to Cover Short, Good Value
about 425 days ago by OptionRadar
about 425 days ago by OptionRadar
http://chart.ly/kst3wg $HAE - Potential short if it breaks the horiz trendline.
about 653 days ago by themeatbaron
about 653 days ago by themeatbaron
$HAE U.S Patent Office confirms validity of Haemonetics patent '983
about 726 days ago by LeakTheNews
about 726 days ago by LeakTheNews
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HAE | 70.17 | +0.46 | +0.66% | 1.753B |
| HA | 5.68 | +0.00 | +0.00% | 288.15M |
| GNVC | 2.52 | +0.02 | +0.80% | 32.40M |
| GNTX | 23.07 | +0.50 | +2.22% | 3.253B |
| GNRC | 25.39 | +0.13 | +0.51% | 1.715B |
| GNOM | 2.61 | -0.39 | -13.00% | 100.26M |
| GNMK | 4.61 | +0.03 | +0.66% | 93.89M |
| GNK | 3.23 | +0.01 | +0.31% | 141.07M |
| GNI | 65.28 | +2.39 | +3.80% | 94.34M |
| GNE | 7.07 | +0.06 | +0.86% |